Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...
Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...
The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered ...
The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered ...
Scientists at the University of Lausanne (UNIL) and University center Unisanté classified 35 commonly used drugs in Switzerland based on their impact on the aquatic biodiversity. The aim of this ...
In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback